Eli Lilly (LLY)
(Delayed Data from NYSE)
$865.97 USD
+8.50 (0.99%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $866.55 +0.58 (0.07%) 4:48 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
LLY 865.97 +8.50(0.99%)
Will LLY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for LLY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LLY
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
Should You Invest in the Vanguard Health Care ETF (VHT)?
LLY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
The 5 Most Important Stocks to Watch During Q2 Earnings Season
Other News for LLY
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
See How Eli Lilly Ranks Among Analysts' Top Picks With Strong Buyback Activity
Healthcare 2024 Second Half Outlook
Morphic price target raised by $27 at Stifel, here's why
The Top 20 Highest Quality Companies In The World